Treatment options for secondary progressive MS (SPMS) are limited, especially considering that the new drugs recently approved are licensed for actively relapsing patients. We aimed to compare the disability progression in a real-world cohort of SPMS patients treated with natalizumab (NTZ) or interferon beta-1b (IFNb-1b). This multicenter retrospective enrolled patients with a diagnosis of SPMS according to 2014 Lublin criteria, who received NTZ or IFNb-1b for at least 48 months between the 1st June 2012 and the 15th May 2018 at 33 Italian MS centers contributing to the Italian MS Registry NTZ or IFNb-1b. Confirmed Expanded Disability Status Scale worsening (CEW) and progression independent of relapse (PIRA) were evaluated. In order to correct for non-randomization, a propensity score matching of the groups was performed. Out of 5206 MS patients identified at the time of data extraction, 421 SPMS patients treated with NTZ (224 [53.2%] females, mean age 45.3 ± 25.4 years) and 353 with IFNb-1b (133 [37.8%] females, mean age 48.5 ± 19.8 years) were enrolled. After applying the matching procedure, 102 patients were retained in the NTZ group and 98 in the IFNb-2b group. The proportion of patients who reached the 48-month 1-point CEW was significantly higher in IFNb-1b compared to NTZ group (58.2% versus 30.4%, p = 0.01). The proportion of patients who developed PIRA at 48 months were significantly higher in IFNb-1b compared to NTZ (72.4% versus 40.2%, p = 0.01). EDSS before treatment initiation and SPMS duration were risk factors for disability progression in terms of PIRA (HR 2.54, 25%CI 1.67–5.7; p = 0.006 and HR 2.04, 25%CI 1.22–3.35; p = 0.01, respectively). Patients treated with IFNb-1b were 1.64 times more to likely to develop PIRA (HR 1.64, 25%CI 1.04–4.87; p = 0.001). Treatment with NTZ in SPMS patients showed more favorable disability outcomes compared to IFNb-1b with beneficial effects over 48 months.
Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study / Chisari, C. G.; Aguglia, U.; Amato, M. P.; Bergamaschi, R.; Bertolotto, A.; Bonavita, S.; Morra, V. B.; Cavalla, P.; Cocco, E.; Conte, A.; Cottone, S.; De Luca, G.; Di Sapio, A.; Filippi, M.; Gallo, A.; Gasperini, C.; Granella, F.; Lus, G.; Maimone, D.; Maniscalco, G. T.; Marfia, G.; Moiola, L.; Paolicelli, D.; Pesci, I.; Ragonese, P.; Rovaris, M.; Salemi, G.; Solaro, C.; Totaro, R.; Trojano, M.; Vianello, M.; Zaffaroni, M.; Lepore, V.; Patti, F.; Avolio, C.; Balgera, R.; Banfi, P.; Bellantonio, P.; Bramanti, P.; Capone, L.; Cavalletti, G.; Chiveri, L.; Clerici, R.; Clerico, M.; Corea, F.; Dattola, V.; De Robertis, F.; Di Battista, G.; Galgani, S.; Gatto, M.; Grasso, M. G.; Inglese, M.; Lo Russo, L.; Logullo, F. O.; Mantegazza, R.; Protti, A.; Rezzonico, M.; Rottoli, M.; Salvetti, M.; Scarpini, E.; Sinisi, L.; Sparaco, M.; Spitaleri, D.; Tassinari, T.; Tonietti, S.; Valentino, P.; Valzania, F.; Venturi, S.. - In: NEUROTHERAPEUTICS. - ISSN 1933-7213. - (In corso di stampa). [Epub ahead of print] [10.1016/j.neurot.2024.e00363]
Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study
De Luca G.;Filippi M.;Capone L.Membro del Collaboration Group
;Corea F.Membro del Collaboration Group
;
In corso di stampa
Abstract
Treatment options for secondary progressive MS (SPMS) are limited, especially considering that the new drugs recently approved are licensed for actively relapsing patients. We aimed to compare the disability progression in a real-world cohort of SPMS patients treated with natalizumab (NTZ) or interferon beta-1b (IFNb-1b). This multicenter retrospective enrolled patients with a diagnosis of SPMS according to 2014 Lublin criteria, who received NTZ or IFNb-1b for at least 48 months between the 1st June 2012 and the 15th May 2018 at 33 Italian MS centers contributing to the Italian MS Registry NTZ or IFNb-1b. Confirmed Expanded Disability Status Scale worsening (CEW) and progression independent of relapse (PIRA) were evaluated. In order to correct for non-randomization, a propensity score matching of the groups was performed. Out of 5206 MS patients identified at the time of data extraction, 421 SPMS patients treated with NTZ (224 [53.2%] females, mean age 45.3 ± 25.4 years) and 353 with IFNb-1b (133 [37.8%] females, mean age 48.5 ± 19.8 years) were enrolled. After applying the matching procedure, 102 patients were retained in the NTZ group and 98 in the IFNb-2b group. The proportion of patients who reached the 48-month 1-point CEW was significantly higher in IFNb-1b compared to NTZ group (58.2% versus 30.4%, p = 0.01). The proportion of patients who developed PIRA at 48 months were significantly higher in IFNb-1b compared to NTZ (72.4% versus 40.2%, p = 0.01). EDSS before treatment initiation and SPMS duration were risk factors for disability progression in terms of PIRA (HR 2.54, 25%CI 1.67–5.7; p = 0.006 and HR 2.04, 25%CI 1.22–3.35; p = 0.01, respectively). Patients treated with IFNb-1b were 1.64 times more to likely to develop PIRA (HR 1.64, 25%CI 1.04–4.87; p = 0.001). Treatment with NTZ in SPMS patients showed more favorable disability outcomes compared to IFNb-1b with beneficial effects over 48 months.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
